Financière de Tubize S.A.
TUB
Clasificación en acciones
#1953
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Precio por acción
$238.53
Capitalización bursátil
$10.62B
Cambio (1 día)
17.74%
Cambio (1 año)
-9.51%
País
BE
Comercio Financière de Tubize S.A. (TUB)
Categoría
Healthcare
Historial del precio de la acción de Financière de Tubize S.A. (TUB)
Precio más alto de cierre: $206.81 el 2026-10-01
Precio más bajo de cierre: $2.36 el 1987-01-01
Precio más bajo de cierre: $2.36 el 1987-01-01
Historial del precio de la acción de Financière de Tubize S.A. desde 1987 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -1.58% |
| 2025 | 71.69% |
| 2024 | 89.17% |
| 2023 | 4.67% |
| 2022 | -24.92% |
| 2021 | -0.07% |
| 2020 | 38.99% |
| 2019 | -0.27% |
| 2018 | -5.64% |
| 2017 | 24.16% |
| 2016 | -18.59% |
| 2015 | 13.12% |
| 2014 | 6.33% |
| 2013 | 41.09% |
| 2012 | 41.21% |
| 2011 | 6.11% |
| 2010 | -18.32% |
| 2009 | 101.99% |
| 2008 | -60.68% |
| 2007 | -34.72% |
| 2006 | 41.02% |
| 2005 | 10.45% |
| 2004 | 49.88% |
| 2003 | 30.83% |
| 2002 | -23.89% |
| 2001 | 12.33% |
| 2000 | -12.76% |
| 1999 | -43.88% |
| 1998 | 54.68% |
| 1997 | 79.87% |
| 1996 | 185.63% |
| 1995 | 55.94% |
| 1994 | 7.19% |
| 1993 | 19.56% |
| 1992 | -2.56% |
| 1991 | -0.97% |
| 1990 | -4.99% |
| 1989 | 97.32% |
| 1988 | 29.77% |
| 1987 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
